Identifying predictors for comorbidities related mortality versus pancreatic cancer related mortality in patients with intraductal papillary mucinous neoplasm
United European Gastroenterology Journal · 2024-06 · 12 (5) · 614-626
DOI: 10.1002/ueg2.12540 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 17.02.2024. Verfasst von Katsunori Sekine und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Kohnodai Hospital, Ichikawa, Chiba, Japan. Hauptthemen laut MEDLINE: Comorbidity, Pancreatic Neoplasms, Pancreatic Intraductal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Emerging and Re-emerging Infectious Diseases, Smoking Research Foundation, Takeda Science Foundation, Tokyo Medical University Cancer Research Foundation, and AMED Research Program on HIV/AIDS, the Ministry of Health, Labour and Welfare, Japan.
Abstract (Originalsprache)
Backgrounds Few data are available for surveillance decisions focusing on factors related to mortality, as the primary outcome, in intraductal papillary mucinous neoplasm (IPMN) patients.
Aims
We aimed to identify imaging features and patient backgrounds associated with mortality risks by comparing pancreatic cancer (PC) and comorbidities.
Methods
We retrospectively conducted a multicenter long‐term follow‐up of 1864 IPMN patients. Competing risk analysis was performed for PC‐ and comorbidity‐related mortality.
Results
During the median follow‐up period of 5.5 years, 14.0% (261/1864) of patients died. Main pancreatic duct ≥5 mm and mural nodules were significantly related to all‐cause and PC‐related mortality, whereas cyst ≥30 mm did not relate. In 1730 patients without high‐risk imaging features, 48 and 180 patients died of PC and comorbidity. In the derivation cohort, a prediction model for comorbidity‐related mortality was created, comprising age, cancer history, diabetes mellitus complications, chronic heart failure, stroke, paralysis, peripheral artery disease, liver cirrhosis, and collagen disease in multivariate analysis. If a patient had a 5 score, 5‐ and 10‐year comorbidity‐related mortality is estimated at 18.9% and 50.2%, respectively, more than 7 times higher than PC‐related mortality. The model score was also significantly associated with comorbidity‐related mortality in a validation cohort.
Conclusions
This study demonstrates main pancreatic duct dilation and mural nodules indicate risk of PC‐related mortality, identifying patients who need periodic examination. A comorbidity‐related mortality prediction model based on the patient's age and comorbidities can stratify patients who do not require regular tests, especially beyond 5 years, among IPMN patients without high‐risk features. Clinical trial registration T2022‐0046.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Kohnodai Hospital, Ichikawa, Chiba, Japan.
- Department of Gastroenterological Endoscopy, Tokyo Medical University, Tokyo, Japan.
- Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo, Japan.
- Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan.
- Department of Radiology, National Center for Global Health and Medicine, Kohnodai Hospital, Ichikawa, Chiba, Japan.
ORCID-Profile: Katsunori Sekine, Naoyoshi Nagata, Yuya Hisada
Förderung
- Emerging and Re-emerging Infectious Diseases
- Smoking Research Foundation, Takeda Science Foundation, Tokyo Medical University Cancer Research Foundation, and AMED Research Program on HIV/AIDS
- the Ministry of Health, Labour and Welfare, Japan
- JSPS KAKENHI
Zitieren
APA
Sekine, K., Nagata, N., Hisada, Y., Yamamoto, K., Mukai, S., Tsuchiya, T., Machitori, A., Kojima, Y., Yada, T., Yamamoto, N., Uemura, N., Itoi, T., & Kawai, T. (2024). Identifying predictors for comorbidities related mortality versus pancreatic cancer related mortality in patients with intraductal papillary mucinous neoplasm. United European Gastroenterology Journal, 12(5), 614-626. https://doi.org/10.1002/ueg2.12540
Vancouver
Sekine K, Nagata N, Hisada Y, Yamamoto K, Mukai S, Tsuchiya T, et al. Identifying predictors for comorbidities related mortality versus pancreatic cancer related mortality in patients with intraductal papillary mucinous neoplasm. United European Gastroenterology Journal. 2024;12(5):614-626. doi:10.1002/ueg2.12540
BibTeX
@article{Sekine2024,
author = {Sekine, Katsunori and Nagata, Naoyoshi and Hisada, Yuya and Yamamoto, Kenjiro and Mukai, Shuntaro and Tsuchiya, Takayoshi and Machitori, Akihiro and Kojima, Yasushi and Yada, Tomoyuki and Yamamoto, Natsuyo and Uemura, Naomi and Itoi, Takao and Kawai, Takashi},
title = {Identifying predictors for comorbidities related mortality versus pancreatic cancer related mortality in patients with intraductal papillary mucinous neoplasm},
journal = {United European Gastroenterology Journal},
year = {2024},
volume = {12},
number = {5},
pages = {614--626},
doi = {10.1002/ueg2.12540}
}
EUVIMED